Biocon Limited

rs,

7, 2022 To, The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523 Dear Sir/Madam, Subject: Investor Presentati

Rs. 8,397

T E D B I O C O N L I M I T E D 5 5 Biocon Today: Strategically poised for a strong global play Rs. 8,397 Cr | $1.1bn Revenue* ~15,000 Total Employees* ~1,300 Patents* 120+ Countries where our products

13%

o Top 5 among global pharma & biotech employer since 2012 o Published Human Rights Policy o 13% revenue in gross R&D spend (Ex Syngene) o Recognized by UN Women for efforts to promote divers

Rs. 11 Crore

o Recognized by UN Women for efforts to promote diversity o 13% increase in women in workforce o Rs. 11 Crore in CSR Spend o 120+ students graduated from Biocon Academy o 58% electricity came from green pow

58%

n women in workforce o Rs. 11 Crore in CSR Spend o 120+ students graduated from Biocon Academy o 58% electricity came from green power o 100% waste water recycled & reused o 118K tCO2 GHG offset

100%

R Spend o 120+ students graduated from Biocon Academy o 58% electricity came from green power o 100% waste water recycled & reused o 118K tCO2 GHG offset o Board Committees, policies for global g

₹580

ed vertically integrated formulation, Mycophenolic Acid Delayed Release tablet in the US Revenue ₹580Cr ₹486Cr +19% Received approvals for Lenalidomide in the EU, Fingolimod capsules in the UAE and

₹486

cally integrated formulation, Mycophenolic Acid Delayed Release tablet in the US Revenue ₹580Cr ₹486Cr +19% Received approvals for Lenalidomide in the EU, Fingolimod capsules in the UAE and Rosuvas

19%

egrated formulation, Mycophenolic Acid Delayed Release tablet in the US Revenue ₹580Cr ₹486Cr +19% Received approvals for Lenalidomide in the EU, Fingolimod capsules in the UAE and Rosuvastatin Ta

₹63

ility located in Biocon Park, Bengaluru On track to qualify & validate Vizag API facility in FY23 ₹63Cr ₹29Cr +116% 11% of revenue 6% of revenue Classified as Restricted B I O C O N L I M I T E D

₹29

ocated in Biocon Park, Bengaluru On track to qualify & validate Vizag API facility in FY23 ₹63Cr ₹29Cr +116% 11% of revenue 6% of revenue Classified as Restricted B I O C O N L I M I T E D B I O

116%

n Biocon Park, Bengaluru On track to qualify & validate Vizag API facility in FY23 ₹63Cr ₹29Cr +116% 11% of revenue 6% of revenue Classified as Restricted B I O C O N L I M I T E D B I O C O N L I

Entering adjacencies in communicable disease

1

Entering adjacencies in communicable disease

infectious disease antibodies and vaccines Key Commercial Products (COVID -19) Recent Collaborations 50,000+ lives impacted Continued portfolio expansion Classified as Restricted B I O C O N L I M I T E D B I O C O N L I M I T E D B I O C O N L I M I T E D 18 18 Asset-light entry into vaccines through SILS alliance 1 2 3 B B L R I G H T S Access to 100m doses of vaccines annually for ~15 years Commercialization rights of the SILS portfolio for global markets BBL to have committed revenue stream and related margins from H2 FY23 Alliance to commercialize SILS COVID portfolio and other next generation vaccines Classified as Restricted B I O C O N L I M I T E D B I O C O N L I M I T E D B I O C O N L I M I T E D 19 19 Comprehensive portfolio of 20 biosimilars and vaccines… Therapeutic Area Molecule US Dev. Markets: ex-US MoW4 Commentary B I O S I M I L A R P R O D U C T S T A T U S Oncology Immunology Diabetes Pegfilgrastim1 Trastuzumab1 Bevacizumab1 Denosumab Pertuzumab1 Adalimumab1,2 Eta